Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

• Status: Completed
• Trial end date: 2006-06-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: Angiopeptin; Lanreotide; Octreotide; Somatostatin

Criteria

Inclusion Criteria:

• Clinical diagnosis of acromegaly

• The patient must have been tested at Week -4 (4 weeks prior to the Baseline visit) and shown to have a GH level <10 mU/L.

• The patient must have been treated with a stable dose of octreotide LAR for at least four months prior to study entry

• Life expectancy of at least 2 years

Exclusion Criteria:

• Adenectomy within past 6 months, or likely during study period

• Radiotherapy for acromegalic disease within 1 year, or likely during study period

• Unstable concomitant dopamine agonist therapy